Glaukos (GKOS)
NYSE:GKOS
Want to see GKOS full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.24Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted strong commercial execution and meaningful growth: record Q1 revenue (+41% reported), raised guidance, robust U.S. glaucoma performance driven by iDose TR, encouraging early commercial and access milestones for Epioxa (including CMS J-code and >100M covered lives), improved gross margin, and a deep clinical pipeline with clear regulatory timelines. Near-term challenges include payer adoption frictions for Epioxa during the miscellaneous J-code period, expected quarter-to-quarter volatility in Corneal Health during the Photrexa-to-Epioxa transition (notably a Q2 dip), potential international competitive and currency headwinds, modestly higher operating expenses to fund launches, and residual policy/LCD risk for interventional glaucoma. Overall, the positive commercial momentum, material guidance raise, margin accretion, and pipeline progress materially outweigh the near-term operational and access headwinds.Company Guidance
Record Consolidated Net Sales and Raised Guidance
Q1 consolidated net sales of $150.6M, up 41% reported and 39% constant currency year-over-year. Raised full-year 2026 net sales guidance to $620M–$635M (from $600M–$620M).
U.S. Glaucoma Franchise Outperformance Driven by iDose TR
Record U.S. glaucoma net sales of $93.5M, growing 58% YoY. iDose TR generated approximately $54M in Q1 and was cited as a primary driver of the franchise's strong performance.
International Glaucoma Growth
International glaucoma record net sales of $35.8M, up 23% reported and 16% constant currency YoY, with contributions from iStent Infinite following EU MDR certification and launch.
Corneal Health and Epioxa Early Commercial Progress
Corneal Health net sales of $21.3M, up 15% YoY, including combined Fotrex (Fetrexan) and very early Epioxa sales of $17.7M. Epioxa achieved commercial availability and early encouraging surgeon feedback.
Epioxa Market-Access Milestones
Secured CMS product-specific J-code J2789 effective July 1, 2026. Early coverage pathways established for >100M covered commercial lives including 4 of the 5 largest payers. Site-of-care network currently serves ~65% of U.S. population with pipeline to ~95%.
iDose Clinical and Reimbursement Momentum
iDose supported by 22 peer‑reviewed publications and multiple active Phase IV studies. Broad payer access: ~99% of commercial & Medicare Advantage patients have an access pathway and ~50% sit in plans with specific policy language. Readministration (reimplantation) procedures observed post-approval.
Strong Gross Margin and Operational Discipline
Group gross margin of 84% in Q1, up ~120 basis points YoY. Company reiterates full-year gross margin expectation of 84%–86% and is focused on operating leverage and cash-flow breakeven.
Robust Pipeline and Product Timelines
Pipeline spans 5 therapeutic platforms with 13 disclosed programs. Key timelines: iDose Trio clinical study complete, planned filing by end of 2026 and targeted approval late 2027; ongoing pivotal trials for iDose TREX, iStent Infinite and PreserFlo MicroShunt; KC screening device planned introduction late 2026.
GKOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GKOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $116.96 | $143.67 | +22.84% |
Feb 17, 2026 | $106.64 | $121.00 | +13.47% |
Oct 29, 2025 | $77.09 | $87.80 | +13.89% |
Jul 30, 2025 | $94.05 | $86.09 | -8.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Glaukos (GKOS) report earnings?
Glaukos (GKOS) is schdueled to report earning on Aug 05, 2026, After Close (Confirmed).
What is Glaukos (GKOS) earnings time?
Glaukos (GKOS) earnings time is at Aug 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GKOS EPS forecast?
GKOS EPS forecast for the fiscal quarter 2026 (Q2) is -0.21.